Skip Navigation


JAC Advance Access originally published online on March 16, 2005
Journal of Antimicrobial Chemotherapy 2005 55(5):601-607; doi:10.1093/jac/dki079
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
55/5/601    most recent
dki079v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (63)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Mouton, J. W.
Right arrow Articles by Drusano, G. L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Mouton, J. W.
Right arrow Articles by Drusano, G. L.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2005. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. For Permissions, please e-mail: journals.permissions{at}oupjournals.org

Leading article

Standardization of pharmacokinetic/pharmacodynamic (PK/PD) terminology for anti-infective drugs: an update

Johan W. Mouton1,*, Michael N. Dudley2, Otto Cars3, Hartmut Derendorf4 and George L. Drusano5

1 Department of Medical Microbiology and Infectious Diseases, Canisius Wilhelmina Hospital, Weg door Jonkerbos 100, 6532 sz Nijmegen, The Netherlands; 2 Diversa Corp., San Diego, CA; 4 Department of Pharmaceutics, University of Florida, Gainesville, FL; 5 Ordway Research Institute, Albany, New York, NY, USA; 3 Department of Infectious Diseases, Uppsala University Hospital, Uppsala, Sweden

* Corresponding author. Tel: +31-24-3657514; Fax: +31-24-3657516; Email: mouton{at}cwz.nl

Interest in the relationships between the pharmacokinetics (PK) and pharmacodynamics (PD) of antimicrobial agents has increased over recent years. Since the appearance 2 years ago of our first article describing terminology in PK/PD, the field has continued to expand rapidly, urgently requiring an update. This paper describes in a uniform manner the use of PK/PD expressions for antimicrobial agents, and their units.

Keywords: AUC/MIC , T>MIC , probability of target attainment , cumulative fraction of response , protein binding


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 J Antimicrob ChemotherHome page
J. A. Roberts, C. M. J. Kirkpatrick, M. S. Roberts, T. A. Robertson, A. J. Dalley, and J. Lipman
Meropenem dosing in critically ill patients with sepsis and without renal dysfunction: intermittent bolus versus continuous administration? Monte Carlo dosing simulations and subcutaneous tissue distribution
J. Antimicrob. Chemother., July 1, 2009; 64(1): 142 - 150.
[Abstract] [Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
C. B. Landersdorfer, M. Kinzig, J. B. Bulitta, F. F. Hennig, U. Holzgrabe, F. Sorgel, and J. Gusinde
Bone Penetration of Amoxicillin and Clavulanic Acid Evaluated by Population Pharmacokinetics and Monte Carlo Simulation
Antimicrob. Agents Chemother., June 1, 2009; 53(6): 2569 - 2578.
[Abstract] [Full Text] [PDF]

Home page
 J Antimicrob ChemotherHome page
G. G. Zhanel, D. Voth, K. Nichol, J. A. Karlowsky, A. M. Noreddin, and D. J. Hoban
Pharmacodynamic activity of ceftobiprole compared with vancomycin versus methicillin-resistant Staphylococcus aureus (MRSA), vancomycin-intermediate Staphylococcus aureus (VISA) and vancomycin-resistant Staphylococcus aureus (VRSA) using an in vitro model
J. Antimicrob. Chemother., May 19, 2009; (2009) dkp176v1.
[Abstract] [Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
S. Schmidt, K. Rock, M. Sahre, O. Burkhardt, M. Brunner, M. T. Lobmeyer, and H. Derendorf
Effect of Protein Binding on the Pharmacological Activity of Highly Bound Antibiotics
Antimicrob. Agents Chemother., November 1, 2008; 52(11): 3994 - 4000.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
J.-B. Michel, P. J. Yeh, R. Chait, R. C. Moellering Jr., and R. Kishony
Drug interactions modulate the potential for evolution of resistance
PNAS, September 30, 2008; 105(39): 14918 - 14923.
[Abstract] [Full Text] [PDF]

Home page
 J Antimicrob ChemotherHome page
R. De Jongh, R. Hens, V. Basma, J. W. Mouton, P. M. Tulkens, and S. Carryn
Continuous versus intermittent infusion of temocillin, a directed spectrum penicillin for intensive care patients with nosocomial pneumonia: stability, compatibility, population pharmacokinetic studies and breakpoint selection
J. Antimicrob. Chemother., February 1, 2008; 61(2): 382 - 388.
[Abstract] [Full Text] [PDF]

Home page
 J Antimicrob ChemotherHome page
K. Ikawa, N. Morikawa, N. Urakawa, K. Ikeda, H. Ohge, and T. Sueda
Peritoneal penetration of doripenem after intravenous administration in abdominal-surgery patients
J. Antimicrob. Chemother., December 1, 2007; 60(6): 1395 - 1397.
[Abstract] [Full Text] [PDF]

Home page
 J Antimicrob ChemotherHome page
P.-L. Toutain, A. Bousquet-Melou, and M. Martinez
AUC/MIC: a PK/PD index for antibiotics with a time dimension or simply a dimensionless scoring factor?
J. Antimicrob. Chemother., December 1, 2007; 60(6): 1185 - 1188.
[Abstract] [Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
J. W. Mouton, N. Punt, and A. A. Vinks
Concentration-Effect Relationship of Ceftazidime Explains Why the Time above the MIC Is 40 Percent for a Static Effect In Vivo
Antimicrob. Agents Chemother., September 1, 2007; 51(9): 3449 - 3451.
[Abstract] [Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
I. Odenholt, E. Lowdin, and O. Cars
Pharmacodynamic Effects of Telavancin against Methicillin-Resistant and Methicillin-Susceptible Staphylococcus aureus Strains in the Presence of Human Albumin or Serum and in an In Vitro Kinetic Model
Antimicrob. Agents Chemother., September 1, 2007; 51(9): 3311 - 3316.
[Abstract] [Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
V. Plasencia, N. Borrell, M. D. Macia, B. Moya, J. L. Perez, and A. Oliver
Influence of High Mutation Rates on the Mechanisms and Dynamics of In Vitro and In Vivo Resistance Development to Single or Combined Antipseudomonal Agents
Antimicrob. Agents Chemother., July 1, 2007; 51(7): 2574 - 2581.
[Abstract] [Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
J. B. Bulitta, S. B. Duffull, M. Kinzig-Schippers, U. Holzgrabe, U. Stephan, G. L. Drusano, and F. Sorgel
Systematic Comparison of the Population Pharmacokinetics and Pharmacodynamics of Piperacillin in Cystic Fibrosis Patients and Healthy Volunteers
Antimicrob. Agents Chemother., July 1, 2007; 51(7): 2497 - 2507.
[Abstract] [Full Text] [PDF]

Home page
 J Antimicrob ChemotherHome page
G. G. Zhanel, S. Derkatch, N. Laing, A. M. Noreddin, and D. J. Hoban
Pharmacodynamic activity of ertapenem versus penicillin-susceptible and penicillin-non-susceptible Streptococcus pneumoniae using an in vitro model
J. Antimicrob. Chemother., January 1, 2007; 59(1): 144 - 147.
[Abstract] [Full Text] [PDF]

Home page
 J Antimicrob ChemotherHome page
J. F. Roos, J. Bulitta, J. Lipman, and C. M. J. Kirkpatrick
Pharmacokinetic-pharmacodynamic rationale for cefepime dosing regimens in intensive care units
J. Antimicrob. Chemother., November 1, 2006; 58(5): 987 - 993.
[Abstract] [Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
A. M. Haritova, N. V. Rusenova, P. R. Parvanov, L. D. Lashev, and J. Fink-Gremmels
Integration of Pharmacokinetic and Pharmacodynamic Indices of Marbofloxacin in Turkeys
Antimicrob. Agents Chemother., November 1, 2006; 50(11): 3779 - 3785.
[Abstract] [Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
F. M. E. Wagenlehner, M. Kinzig-Schippers, U. Tischmeyer, C. Wagenlehner, F. Sorgel, and K. G. Naber
Urinary Bactericidal Activity of Extended-Release Ciprofloxacin (1,000 Milligrams) versus Levofloxacin (500 Milligrams) in Healthy Volunteers Receiving a Single Oral Dose
Antimicrob. Agents Chemother., November 1, 2006; 50(11): 3947 - 3949.
[Abstract] [Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
I. A. J. M. Bakker-Woudenberg, M. T. ten Kate, W. H. F. Goessens, and J. W. Mouton
Effect of Treatment Duration on Pharmacokinetic/Pharmacodynamic Indices Correlating with Therapeutic Efficacy of Ceftazidime in Experimental Klebsiella pneumoniae Lung Infection.
Antimicrob. Agents Chemother., September 1, 2006; 50(9): 2919 - 2925.
[Abstract] [Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
C. Buerger, N. Plock, P. Dehghanyar, C. Joukhadar, and C. Kloft
Pharmacokinetics of unbound linezolid in plasma and tissue interstitium of critically ill patients after multiple dosing using microdialysis.
Antimicrob. Agents Chemother., July 1, 2006; 50(7): 2455 - 2463.
[Abstract] [Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
E. Giannoni, P. Moreillon, J. Cotting, A. Moessinger, J. Bille, L. Decosterd, G. Zanetti, P. Majcherczyk, and D. Bugnon
Prospective determination of plasma imipenem concentrations in critically ill children.
Antimicrob. Agents Chemother., July 1, 2006; 50(7): 2563 - 2568.
[Abstract] [Full Text] [PDF]

Home page
 J Antimicrob ChemotherHome page
G. G. Zhanel, J. James, S. Derkatch, N. Laing, A. M. Noreddin, and D. J. Hoban
Pharmacodynamic activity of garenoxacin against ciprofloxacin-resistant Streptococcus pneumoniae
J. Antimicrob. Chemother., July 1, 2006; 58(1): 112 - 116.
[Abstract] [Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
M. D. Macia, N. Borrell, M. Segura, C. Gomez, J. L. Perez, and A. Oliver
Efficacy and Potential for Resistance Selection of Antipseudomonal Treatments in a Mouse Model of Lung Infection by Hypermutable Pseudomonas aeruginosa
Antimicrob. Agents Chemother., March 1, 2006; 50(3): 975 - 983.
[Abstract] [Full Text] [PDF]

Home page
 J Antimicrob ChemotherHome page
D. S. Burgess and C. R. Frei
Comparison of {beta}-lactam regimens for the treatment of Gram-negative pulmonary infections in the intensive care unit based on pharmacokinetics/pharmacodynamics
J. Antimicrob. Chemother., November 1, 2005; 56(5): 893 - 898.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.